Janssen Search
Search results
Opening Vaccines Launch Facility
Article Type: Other About the Symposium The speakers include: Bruno Bruins- Minister for Medical Care and Sport of the Netherlands, Pierre Meulien of the EU’s Innovative Medicines Initiative (IMI), Jayasree K. Iyer of the Access to Vaccines Index (ATVI) ...
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma
Sep 20, 2024 Belgium Recommendation supported by findings from quadruplet therapy PERSEUS study with daratumumab subcutaneous (SC) formulation in the frontline setting Findings showed 60 percent reduction in risk of disease progression or death with ...
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
Mar 06, 2024 Belgium Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk of progression or death, compared to standard of care regimen. [1] BEERSE, ...
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
Sep 15, 2024 Spain Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive BARCELONA, September 15, 2024 /PR Newswire ...
Pediatric HIV Donation
Improving Access for Children Living with HIV At Janssen, we are dedicated to doing our part to help children and young people living with HIV thrive and reach adulthood. Our company has a long history of working to improve the lives and well-being of ...
Patrick Loerch, Ph.D.
PATRICK LOERCH, PH.D. GLOBAL HEAD, DATA SCIENCES & PREVENTION BIOMARKERS WORLD WITHOUT DISEASE ACCELERATOR As Global Head, Data Sciences & Prevention Biomarkers, World Without Disease Accelerator (WWDA), Patrick leads a team focused on developing ...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery
May 03, 2024 Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localized prostate cancer (HRLPC) experience disease recurrence within two years of surgery SAN ANTONIO, May 3, ...
Late-Breaking Phase 3 A DUE Data Show Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Hemodynamics versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)
Mar 06, 2023 United States Study findings presented during the American College of Cardiology’s 72nd Annual Scientific Session & Expo Together With World Heart Federation’s World Congress of Cardiology European Society of Cardiology/European ...
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis
Mar 11, 2024 United States Submission is supported by data from the Phase 3 QUASAR program, which showed a significantly greater percentage of patients with moderately to severely active ulcerative colitis who received TREMFYA ® achieved clinical ...
Janssen Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy EDURANT®
Jul 28, 2023 United States Parallel application also submitted to European Medicines Agency If approved, EDURANT ® (rilpivirine) in combination with other antiretroviral therapies would offer a new HIV-1 treatment option for younger children TITUSVILLE, N ...